Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

GeoVax Labs (GOVX) Research & Development (2016 - 2025)

GeoVax Labs' Research & Development history spans 16 years, with the latest figure at $3.0 million for Q4 2025.

  • Quarterly results put Research & Development at $3.0 million for Q4 2025, down 60.64% from a year ago — trailing twelve months through Dec 2025 was $18.1 million (down 23.58% YoY), and the annual figure for FY2025 was $18.1 million, down 23.58%.
  • Research & Development for Q4 2025 was $3.0 million at GeoVax Labs, down from $5.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $12.9 million in Q4 2021 to a low of $602783.0 in Q1 2021.
  • The 5-year median for Research & Development is $4.4 million (2024), against an average of $4.4 million.
  • The sharpest move saw Research & Development soared 1602.55% in 2021, then tumbled 70.8% in 2022.
  • Year by year, Research & Development stood at $12.9 million in 2021, then tumbled by 70.8% to $3.8 million in 2022, then soared by 65.59% to $6.2 million in 2023, then grew by 22.04% to $7.6 million in 2024, then crashed by 60.64% to $3.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $3.0 million, $5.0 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.